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Purpose: Limited guidance exists regarding the relative effectiveness of treatment options for nonmetastatic, operable patients with adenocarcinoma of the esophagus or gastroesophageal junction (GEJ). In this systematic review, the American Radium Society (ARS) gastrointestinal expert panel convened to develop Appropriate Use Criteria (AUC)
evaluating how neoadjuvant and/or adjuvant treatment regimens compared with each other, surgery alone, or definitive
chemoradiation in terms of response to therapy, quality of life, and oncologic outcomes.
Methods and Materials: Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) methodology
was used to develop an extensive analysis of peer-reviewed phase 2R and phase 3 randomized controlled trials as well as
meta-analyses found within the Ovid Medline, Cochrane Central, and Embase databases between 2009 to 2019. These
studies were used to inform the expert panel, which then rated the appropriateness of various treatments in 4 broadly
representative clinical scenarios through a well-established consensus methodology (modified Delphi).
Results: For a medically operable nonmetastatic patient with a cT3 and/or cNþ adenocarcinoma of the esophagus or GEJ
(Siewert I-II), the panel most strongly recommends neoadjuvant chemoradiation. For a cT2N0M0 patient with high-risk features, the panel recommends neoadjuvant chemoradiation as usually appropriate. For patients found to have pathologically
involved nodes (pNþ) who did not receive any neoadjuvant therapy, the panel recommends adjuvant chemoradiation as usually appropriate. These guidelines assess the appropriateness of various dose-fractionating schemes and target volumes.
Conclusions: Chemotherapy and/or radiation regimens for esophageal cancer are still evolving with many areas of active
investigation. These guidelines are intended for the use of practitioners and patients who desire information about the management of operable esophageal adenocarcinoma. Ó 2020 Published by Elsevier Inc.

Introduction
Although esophageal cancer is the 20th most common cancer
in the United States, its high lethality and much higher
prevalence worldwide demand attention.1,2 Adenocarcinoma
of the distal esophagus accounts for approximately two-thirds
of all esophageal cancers in the United States, and approximately half of these are stage III or IV. Radical resection, in
the form of esophagectomy, is the mainstay of curative therapy, but overall outcomes for patients with esophageal
adenocarcinoma remain poor.2,3 Advancements in nonsurgical modalities, including systemic therapy and radiation
therapy (RT), led to the evolution of multidisciplinary therapeutic strategies. It is notable that the 5-year overall survival
(OS) improved from 5% to about 20% during the last 30 years,
suggesting small yet measurable improvements in diagnosis,
staging, treatment, and supportive care.4 The 5-year survival
rates for localized, regional, and distant disease are 47%,
25%, and 5%, respectively, highlighting the importance of
early diagnosis. Geographic variability in esophageal cancer
(preponderance of squamous cell carcinoma (SCC) in the
East vs adenocarcinoma in the West) has led to differences in
the management of this disease around the world.2,3,5 Except
for in situ or early-stage disease, which can be managed with
esophagectomy alone or endoscopic resection, multimodality
therapy integrating neoadjuvant and/or adjuvant chemotherapy and RT with surgery is widely accepted based on
high-level evidence.2,3 Despite these advances, there remains
little guidance regarding the relative effectiveness of the
various treatment options for patients with operable

esophageal adenocarcinoma. Herein, this systematic review
and guidelines intend to provide insights and direction to
practitioners based on the available evidence.

Methodology
The evidence regarding treatment outcomes was assessed
using the Population, Intervention, Comparator, Outcome, and
Study design (PICOS) framework. For the population of
operable patients with adenocarcinoma of the esophagus or
gastroesophageal junction (GEJ), we sought to evaluate how
neoadjuvant or adjuvant treatment compared with each other,
surgery alone, or definitive chemoradiation in terms of
response to therapy, quality of life (QoL), or oncologic outcomes through the assessment of data from randomized
controlled trials (RCTs) and meta-analyses. Trial size required
for inclusion was 50 patients for phase 2R and 3 RCTs and
100 patients for meta-analyses, of whom at least 20 patients
were required to have adenocarcinoma. With librarian assistance we developed literature search strategies using medical
subject headings (MeSH) and combinations of keyword
search terms (Table 1) to address our PICOS question.
An extensive analysis of current medical literature
covering January 1, 2009 to May 28, 2019, from peerreviewed journals indexed in the Ovid Medline, Cochrane
Central, and Embase databases and using the Preferred
Reporting Items for Systematic reviews and Meta-Analyses
(PRISMA) guidelines yielded a comprehensive set of
relevant articles. The literature was reviewed for quality of
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Table 1 Literature search strategy for 2020 American Radium Society (ARS) Appropriate Use Criteria (AUC) for operable
esophageal adenocarcinoma
Set
number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

No. of references
retrieved

Search text
(esophag* or oesophag* or gastroesophag* or “gastro-esophag*” or “gastrooesophag*”).ti,ab,kf.
(cancer* or carcinoma* or neoplas* or adenocarcinoma* or malignan* or tumor* or
tumour*).ti,ab,kf.
1 and 2
exp *Esophageal Neoplasms/
exp *Neoplasms/
exp *Esophagus/
5 and 6
3 or 4 or 7
(resect* or esophagectom* or oesophagectom* or surg* or opera* or adjuvant* or
neoadjuvant*).ti,ab,kf.
exp Esophagectomy/
su.fs.
9 or 10 or 11
(radiotherap* or radiat* or irradiat* or chemoradi* or chemotherap* or adjuvant* or
neoadjuvant*).ti,ab,kf.
exp Radiotherapy/
exp antineoplastic agents/ or exp antineoplastic protocols/
exp combined modality therapy/
rt.fs.
th.fs.
or/13-18
(“phase II*” or “phase 2*” or “phase III*” or “phase 3*” or “meta-analys*” or “metaanalys*”
or “randomi*” or “phase IV*” or “phase 4*”).ti,ab,kf.
clinical trial, phase II/ or clinical trial, phase III/ or clinical trial, phase IV/
exp Meta-Analysis/
validation studies/
exp controlled clinical trial/
or/20-24
8 and 12 and 19 and 25
limit 26 to yrZ”2009 - 2019”
limit 27 to English language
(“non-small cell lung ca*” or “non small cell lung ca*” or “small cell lung ca*” or “NSCLC”
or “SCLC”).ti,ab,kf.
28 not 29

176,096
3,163,127
69,644
40,889
2,780,090
31,869
5498
74,581
2,754,273
9218
1,905,698
3,577,588
1,035,545
176,454
1,094,704
249,945
184,745
1,774,289
3,547,253
768,147
46,443
102,077
95,475
573,006
1,151,901
1698
892
839
70,983
805

Key: Sets 1-8, esophageal adenocarcinoma; sets 9-12, treatment addresses surgery; sets 13-19, treatment addresses systemic therapy and/or radiation;
lines 20-25, limits search to phase 2-4 trials or meta-analyses; set 26, selects for studies contained in each of the 4 prior groups of set themes; sets 27-30,
additional limitations on search including date range and English language, and excluding lung cancer.
Literature search date range: January 1, 2009 to May 28, 2019.
Database: Ovid MEDLINE(R) without revisions.

study design, cohort size, selection bias, and methods of
assessments. Two authors independently screened the
studies and full-text articles to determine the final studies
included in this review, as detailed in Figure 1. Any discrepancies between the reviewers were resolved by
consensus. We reviewed the bibliographies of full articles
for a comprehensive survey, and 8 additional studies were
included; these met all inclusion criteria except publication
date (3 published before 2009). Forward citation chaining
via Web of Science was then performed on the selected
documents to determine whether any eligible articles published no later than May 28, 2019, had been missed by the

searches, and 1 was found, resulting in 52 references.6-57
Study type and quality were assessed via American
Radium Society (ARS) Appropriate Use Criteria (AUC)
methodology (Appendix A).58 The checklist confirming
completion of all essential elements for a PRISMA systematic review may be found in Appendix B, and Appendix
C contains a list of abbreviations. A well-established
consensus methodology (modified Delphi) was used by
the expert panel; panel members had expertise in the
management of esophageal cancer and could rate the
appropriateness of the treatment procedures.59 Disagreement was defined as more than one-third of votes occurring
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Table 2 Clinical condition: Operable esophageal adenocarcinoma
Variant 1: Clinical stage IIB, cT2 cN0 M0 high-grade* (signet-ring) adenocarcinoma of the lower thoracic esophagus noted on
y
EUS, extending 32-36 cm from the incisors in a medically operable patient. No dysphagia present. No elevated FDG uptake
noted on PET.
Treatment
Planned treatment
nCRT
nCT
Surgery alone
S / aCRT
S / aCT
dCRT
S / aRT
If RT: Dose to primary
(if neoadjuvant)
30- 30.6 Gy/15-17 fx
40-41.4 Gy/20-23 fx
45-46 Gy/25-23 fx
50-50.4 Gy/25-28 fx
54 Gy/30 fx
59.4-60 Gy/33-30 fx
If RT: Dose to elective nodes
30- 30.6 Gy/15-17 fx
36 Gy/18-20 fx
40-41.4 Gy/20- 23 fx
45-46 Gy/25-23 fx
50-50.4 Gy/25-28 fx
If RT: Elective nodal regions
Supraclavicular
Mediastinal prevascular and paraortic/
paratracheal/aortopulmonary window
Subcarinal
Paraesophageal
Celiac/paracardial/subdiaphragmatic
Gastrohepatic ligament/lesser curvature
Splenicz

Rating category

Group median rating

Relevant references

SOE

SOR

A
M
Mx
M
Mx
Mx
U

8
5
5x
5
5x
5x
3

17-20
6,7,9,11,12,18,34,35
17-20
36,37,40
37
43,44
37

S
S
S
M
L
L
L

[
[
[
[
[
[

U
A
A
A
Mx
U

2
8
7
8
5x
1

33
14,29
17-20
18-20
18-20,45-47
N/A

L
S
S
M
L
EO

[
[
[
[
[

U
U
A
A
Mx

2
3
8
8
5x

N/A
N/A
44
44
43,44

EO
EO
S
S
S

[
[
[
-

U
Mx

1
5x

14,29
14

M
L

[
-

Mx
A
A
A
U

5x
9
8
8
3

14
14,23,29,33
14,23,29,33
14,23,33
33

L
S
S
S
L

[
[
[
[

Rating: U, usually not appropriate (1-3); M, may be appropriate (4-6); A, usually appropriate (7-9).
Strength of evidence (SOE): S: strong; M: moderate; L: limited; EC: expert consensus; EO: expert opinion.
Strength of recommendation (SOR) of rating category: [: strong; Y: weak; “-”: additional considerations do not strengthen or weaken the panel’s
recommendation.
Abbreviations: aCT Z adjuvant chemotherapy; aCRT Z adjuvant concurrent chemoradiation therapy; aRT Z adjuvant radiation therapy; dCRT Z
definitive concurrent chemoradiation therapy; EUS Z endoscopic ultrasound; FDG Z fluorodeoxyglucose; fx Z fractions; nCT Z neoadjuvant
chemotherapy; nCRT Z neoadjuvant concurrent chemoradiation therapy; PET/CT Z positron emission tomography/computed tomography; poCT Z
perioperative chemotherapy; S Z surgery.
* Tumor size >3 cm, poor differentiation, and/or lymphovascular invasion found on endoscopic resection specimens are associated with higher risk of
upstaging to T3 and/or Nþ20 and neoadjuvant therapy should be considered.
y
Complete solid food dysphagia is associated with increased likelihood of pT3 disease.23
z
Proximal 2 cm of splenic artery region.
x
Disagreement (ie, the variation of the individual ratings from the median rating) indicates panel disagreement on the final recommendation (see
narrative text for definition). Group median rating is set automatically to 5.

outside the rating category. Categories included (1) usually
not appropriate (U, score 1-3); (2) may be appropriate (M,
score 4-6); and (3) usually appropriate (A, score 7-9).
Studies within the introduction and future directions sections are referenced only to provide context but are not
included as the supporting evidence for oncologic interventions. For the RT section, evidence from the literature
search was supplemented by recommendations from an
expert contouring guidelines atlas.60

Summary of Literature Review
Neoadjuvant treatment
Neoadjuvant chemotherapy or perioperative
chemotherapy versus surgery alone
In the meta-analysis of RCTs comparing neoadjuvant
chemotherapy (nCT) or perioperative chemotherapy (poCT)
to surgery alone by Coccolini et al, a subset analysis of
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Table 3 Clinical condition: Operable esophageal adenocarcinoma
Variant 2: Clinical stage IVA, T3 N2 M0 moderately differentiated adenocarcinoma of the gastroesophageal junction (Siewert II)
located 38-43 cm from the incisors in a medically operable patient. Two distal paraesophageal nodes and 3 gastrohepatic nodes
measuring up to 2.5 cm in size noted on EUS and PET/CT.
Treatment
Planned treatment
nCRT
iCT / nCRT / S*
nCT
poCT
dCRT
nCT and aCRT
S / aCRT
S / aCT
S / aRT
Surgery alone
If RT: Dose to involved primary/nodes
(if neoadjuvant)z
30-30.6 Gy/15-17 fx
40-41.4 Gy/20-23 fx
45-46 Gy/25-23 fx
50-50.4 Gy/25-28 fx
54 Gy/30 fx
59.4-60 Gy/33-30 fx
If RT: Dose to elective nodesz
30-30.6 Gy/15-17 fx
36 Gy/18-20 fx
40-41.4 Gy/20-23 fx
45-46 Gy/25-23 fx
50-50.4 Gy/25-28 fx
If RT: Elective nodal regionsz
Supraclavicular
Mediastinal prevascular and
paraortic/paratracheal/aortopulmonary window
Subcarinal
Paraesophageal
Celiac/paracardial/subdiaphragmatic
Gastrohepatic ligament/lesser curvature
Splenicx

Rating category

Group median rating

Relevant references

SOE

SOR

A
A
M
M
My
M
U
U
U
U

9
7
5
5
5y
4
3
2
1
1

13,14,24-26,34,35
21,23
6,7,9,11,12,18,29,34,35
6,8
43,45-48
41
36,37,40
37
37
34,35,43,44

S
M
S
M
M
M
M
L
L
S

[
[
[
[
[
[
[
[
[

U
A
A
A
M
U

2
8
7
8
4
2

33
14,29,44
23,44
21,44
44
44

M
S
S
S
L
L

[
[
[
[
[
[

U
My
A
A
A

3
5y
7.5
7
7

33,44
44
14,29,44
23
21,44

L
L
S
S
S

[
[
[
[

U
U

1
3

14,29
14

M
L

[
[

M
A
A
A
U

5
9
9
9
3

14
14,23,29,33
14,23,29,33
14,23,33
33

L
S
S
S
L

[
[
[
[
[

Rating: U, usually not appropriate (1-3); M, may be appropriate (4-6); A, usually appropriate (7-9).
Strength of evidence (SOE): S: strong; M: moderate; L: limited; EC: expert consensus; EO: expert opinion.
Strength of recommendation (SOR) of rating category: [: strong; Y: weak; “-”: additional considerations do not strengthen or weaken the panel’s
recommendation.
Abbreviations: aCT Z adjuvant chemotherapy; aCRT Z adjuvant concurrent chemoradiation therapy; aRT Z adjuvant radiation therapy; dCRT Z
definitive concurrent chemoradiation therapy; EUS Z endoscopic ultrasound; fx Z fractions; iCT Z induction chemotherapy given before CRT; nCT Z
neoadjuvant chemotherapy; nCRT Z neoadjuvant concurrent chemoradiation therapy; PET/CT Z positron emission tomography/computed tomography;
poCT Z perioperative chemotherapy; S Z surgery.
* Based on encouraging initial results from CALGB 80803.
y
Disagreement (ie, the variation of the individual ratings from the median rating) indicates panel disagreement on the final recommendation (see
narrative text for definition). Group median rating is set automatically to 5.
z
Key radiation points:
1. In the neoadjuvant setting, 40-50.4 Gy in fraction sizes between 1.8 and 2.0 Gy to involved disease and elective nodal areas is preferred. This may
involve a reduced field size to include just the primary tumor after an elective dose to 40-45 Gy.
2. Elective radiation of the paraesophageal, celiac, paracardial, subdiaphragmatic, gastrohepatic ligament, and lesser curvature nodes is preferred for
distal tumors. Subcarinal nodes should be included if paraesophageal nodes extend superiorly to the same axial plane.
x
Proximal 2 cm of splenic artery region.

patients with GEJ adenocarcinoma found that the addition of
chemotherapy improved OS.6 However, it should be noted
that the 3 studies included within this analysis did not
distinguish between Siewert grades, thus limiting the

generalizability to the more proximal Siewert I and II patients,
who are typically regarded as falling within the esophageal
cancer paradigm.7-9 Subset analysis for adenocarcinoma
(67% of the patients) also showed improved OS with the
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Table 4 Clinical condition: Operable esophageal adenocarcinoma
Variant 3: Clinical stage III, T3 N1 M0 adenocarcinoma of the middle thoracic esophagus extending 25-30 cm from the incisors
with its proximal extent just superior to the carina. One adjacent paraesophageal node noted on EUS and PET/CT in a medically
operable patient. Bronchoscopy was negative for trachea-esophageal fistula.
Treatment
Planned treatment
nCRT
iCT / nCRT / S*
nCT and aCRT
dCRT
nCT
poCT
S / aCRT
S / aCT
S / aRT
Surgery alone
If RT: Dose to primary/involved
nodes
(if neoadjuvant)z
30-30.6 Gy/15-17 fx
40-41.4 Gy/20-23 fx
45-46 Gy/25-23 fx
50-50.4 Gy/25-28 fx
54 Gy/30 fx
59.4-60 Gy/33-30 fx
If RT: Dose to elective nodesz
30-30.6 Gy/15-17 fx
36 Gy/18-20 fx
40-41.4 Gy/20-23 fx
45-46 Gy/25-23 fx
50-50.4 Gy/25-28 fx
If RT: Elective nodal regionsz
Supraclavicular
Mediastinal prevascular and
paraortic/paratracheal/
aortopulmonary window
Subcarinal
Paraesophageal
Celiac/paracardial/
subdiaphragmatic
Gastrohepatic ligament/lesser
curvature
Splenicx

Rating category

Group median rating

Relevant references

SOE

SOR

A
A
My
My
M
M
U
U
U
U

9
7
5y
5y
4
4
3
3
3
1

13,14,24-26,34,35
21,23
41
43,45-48
6,7,9,11,12,18,29,34,35
6,8
36,37,40
37
37
34,35,43,44

S
M
L
M
S
L
L
L
L
S

[
[
[
[
[
[
[
[
[

U
A
A
A
My
U

3
8
8
8
5y
2

33
14,29,44
23,44
21,44
44
44

M
S
S
S
L
L

[
[
[
[
[
[

U
U
A
A
My

2
3
8
8
5y

33,44
44
14,29,44
23
21,44

L
L
S
S
S

[
[
[
[
[

My
A

5y
8

14,29
14

M
L

[
[

A
A
My

8
9
5y

14
14,23,29,33
14,23,29,33

L
S
M

[
[
-

My

5y

14,23,33

M

-

U

1

33

L

[

Rating: U, usually not appropriate (1-3); M, may be appropriate (4-6); A, usually appropriate (7-9).
Strength of evidence (SOE): S: strong; M: moderate; L: limited; EC: expert consensus; EO: expert opinion.
Strength of recommendation (SOR) of rating category: [: strong; Y: weak; “-”: additional considerations do not strengthen or weaken the panel’s
recommendation.
Abbreviations: aCT Z adjuvant chemotherapy; aCRT Z adjuvant concurrent chemoradiation therapy; aRT Z adjuvant radiation therapy; dCRT Z
definitive concurrent chemoradiation therapy; EUS Z endoscopic ultrasound; fx Z fractions; iCT Z induction chemotherapy given before CRT; nCT Z
neoadjuvant chemotherapy; nCRT Z neoadjuvant concurrent chemoradiation therapy; PET/CT Z positron emission tomography/computed tomography;
poCT Z perioperative chemotherapy; S Z surgery.
* Based on encouraging initial results from CALGB 80803.
y
Disagreement (ie, the variation of the individual ratings from the median rating) indicates panel disagreement on the final recommendation (see
narrative text for definition). Group median rating is set automatically to 5.
z
Key radiation points
1. Neoadjuvant doses of 40-50.4 Gy in fraction sizes between 1.8 and 2.0 Gy to involved disease and elective nodal areas is preferred. This may
involve a reduced field size to include just the primary tumor after an elective dose to 40-45 Gy.
2. Elective radiation of the paraesophageal, supraclavicular, mediastinal prevascular and paraortic, paratracheal, aortopulmonary window, and
subcarinal nodes is preferred in the setting of neoadjuvant concurrent chemoradiation for adenocarcinoma of the middle thoracic esophagus
extending above the carina.Elective radiation of the celiac, paracardial, subdiaphragmatic, gastrohepatic ligament, and lesser curvature nodes may
be omitted in the setting of neoadjuvant concurrent chemoradiation for adenocarcinoma of the middle thoracic esophagus extending above the
carina with minimal to no involvement of the distal thoracic esophagus.
x
Proximal 2 cm of splenic artery regiony.
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Table 5 Clinical condition: Operable esophageal cancer
Variant 4: After surgery for clinical stage II, T2 N0 M0 moderately differentiated adenocarcinoma of the lower thoracic
esophagus located 30-35 cm from the incisors staged via EUS and PET/CT, final pathology revealed 2 positive nodes indicating
pathologic stage IIIA, pT2 pN1 M0 disease.
Treatment
Planned treatment
aCRT
aCT
aRT
Observation
If RT: Dose to operative bedy
40-41.4 Gy/20-23 fx
45 Gy/25 fx
50-50.4 Gy/25-28 fx
54 Gy/30 fx
59.4-60 Gy/33-30 fx
If RT: Dose to elective nodesy
30-30.6 Gy/15-17 fx
36 Gy/18-20 fx
41.4 Gy/23 fx
45-46 Gy/25-23 fx
50-50.4 Gy/25-28 fx
If RT: Elective regions
Supraclavicular
Mediastinal prevascular and paraortic/
paratracheal/aortopulmonary window
Subcarinal
Paraesophageal
Celiac/paracardial/subdiaphragmatic
Gastrohepatic ligament/lesser curvature
Splenicz
Anastomosis

Rating category

Group median rating

Relevant references

SOE

SOR

A
M
M*
U

8
5
5*
3

36,37,40
37
37
37

S
M
M
S

[
[
[

U
A
A
M
U

3
8
8
5
2

36,37
36,37,40
36,37
36,37
36,37

L
L
M
L
L

[
[
[
[
[

U
U
M
A
A

1
3
4
8
7

N/A
N/A
36,37
36,37,40
36,37

L
L
S
S
S

[
[
[
[
[

U
U

1
3

14,29
14

M
L

[
-

M*
A
A
A
U
A

5*
8.5
8
7.5
2
9

14
14,23,29,33
14,23,29,33
14,23,33
33
36,37,40

L
S
S
S
L
S

[
[
[
[
[

Rating: U, usually not appropriate (1-3); M, may be appropriate (4-6); A, usually appropriate (7-9).
Strength of evidence (SOE): S: strong; M: moderate; L: limited; EC: expert consensus; EO: expert opinion.
Strength of recommendation (SOR) of rating category: [: strong; Y: weak; “-”: additional considerations do not strengthen or weaken the panel’s
recommendation.
Abbreviations: aCT Z adjuvant chemotherapy; aCRT Z adjuvant concurrent chemoradiation therapy; aRT Z adjuvant radiation therapy; EUS Z
endoscopic ultrasound; fx Z fractions; PET/CT Z positron emission tomography/computed tomography.
* Disagreement (ie, the variation of the individual ratings from the median rating) indicates panel disagreement on the final recommendation (see
narrative text for definition). Group median rating is set automatically to 5.
y
Key radiation point: Adjuvant radiation doses between 45 and 50.4 Gy in fraction sizes between 1.8 and 2.0 Gy to the anastomosis and elective nodal
areas are preferred in the adjuvant setting. Doses to the anastomosis of 54 Gy and higher are not preferred.
z
Proximal 2 cm of splenic artery region.

addition of chemotherapy. In a Cochrane review of 13 randomized trials assessing nCT for resectable thoracic esophageal cancer, Kidane et al noted an OS and R0 resection rate
benefit with chemotherapy, although the overall resection
rate, tumor recurrence, and nonfatal complication rates were
not found to be different.10 The potential for increased
toxicity with chemotherapy was noted. However, the OS
benefit was no longer significant on subset analysis of patients
with adenocarcinoma, leading to uncertainty of the potential
benefit for this population. In the United Kingdom Medical
Research Council Oesophageal 02 (MRC OE02) trial, which
comprised the largest population of patients in the Kidane et al
meta-analysis (two-thirds adenocarcinoma), esophageal
cancer patients were randomized to neoadjuvant cisplatin and
fluorouracil (5-FU) versus surgery alone; an improvement in

OS and disease-free survival (DFS) as well as R0 resections
was noted with chemotherapy.11 The next largest proportion
of patients within this meta-analysis was from the Intergroup
0113 study, which involved adenocarcinoma in just over half
the population; this study did not show any OS benefit to nCT
with cisplatin and 5-FU.12 Locoregional failure was equivalent between groups, with a numerically but not significantly
higher number of distant failures in the surgery alone group.
Therefore, nCT appears of borderline benefit given the mixed
results regarding OS.
Neoadjuvant chemoradiation versus surgery alone
Early stage esophageal cancer invading into the muscularis
propria (T2) is not suitable for endoscopic therapies, so
upfront esophagectomy is the preferred therapy for
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Records Identified through database searching:
Ovid Medline: n = 805
Embase: n = 1888
Cochrane Central: n = 1265
Total: n = 3958

SCREENING

Duplicates Excluded:
n = 1172
Titles & Abstracts Screened:
n = 2786
Excluded because of Titles &
Abstracts:
n = 2720

ELIGIBILITY

Full-text articles assessed for eligibility:
n = 66

Total Eligible Studies
Before Backward Citation Chaining:
n = 43

INCLUDED

Total Eligible Studies
Before Forward Citation Chaining:
n = 51

Full-text articles excluded:
Outdated/prior version: n = 14
Insufficient number of
adenocarcinoma patients: n = 3
Poor quality: n = 3
Gastric only: n = 2
Not randomized: n = 1
Total: n = 23
Reviewed reference lists of
eligible studies to find
additional relevant articles
n=8

Reviewed articles citing the
eligible studies to find
additional relevant articles
n=1

Final Total Eligible Studies:
n = 52

Fig. 1.

Study selection flow chart for the systematic review.

operable patients as noted in the National Comprehensive
Cancer Network guidelines.2 However, long-term outcomes
are still suboptimal with surgery alone, suggesting a
possible use of neoadjuvant therapy.13-17 In the randomized, controlled phase 3 trial Federation Francophone de
Cancerologie Digestive (FFCD) 9901, 195 patients (29%
adenocarcinoma) with Union for International Cancer
Control 5th edition stage I or II disease (ie, T1-2N0-1M0 or
T3N0M0) were randomized to receive surgery alone versus
neoadjuvant concurrent chemoradiation therapy (nCRT)
with 45 Gy in 25 fractions and 2 cycles of concomitant
5-FU and cisplatin.17 No difference was seen in OS or R0
resection rate, but the postoperative mortality rate was
significantly worse in the nCRT arm (11.1% vs 3.4%,
P < .049). No difference in distant metastases was noted.
Subset analyses showed no differences in outcomes between adenocarcinoma and SCC patients. Although the
majority of the patients in this trial were T2 (56.4%) and
N0 (72.3%), the number of patients who were both T2 and

N0 was not specified and subset analyses were not performed; thus, definitive conclusions on this patient population cannot be made.
Three contemporaneous meta-analyses were published
investigating whether neoadjuvant therapy (RT with or
without chemotherapy) or upfront surgery leads to optimal
outcomes for T2N0 patients.18-20 Although the R0 resection
rate increased with neoadjuvant therapy in the largest series, which involved 5,433 patients in 9 retrospective
studies,18 this sample size did not translate to improved
OS18-20 or recurrence-free survival18,20 for either adenocarcinoma or SCC patients in any of the 3 meta-analyses.
Of note, more than 80% of the patients in these series
had adenocarcinoma. No differences in anastomotic leak
rates or perioperative mortality were noted.18,20 Kidane
et al found that, in patients proceeding to surgery without
neoadjuvant therapy, the N-stage was upstaged in 33.4% of
cases and either T- or N- stage was upstaged in 41.5% of
cases, although positive emission tomography (PET) and
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endoscopic ultrasound (EUS) use was inconsistent. Because
larger tumor size (>3 cm) and lymphovascular invasion
(LVI) were significant predictors of pathologic upstaging,
the authors suggested these factors, along with high-grade
histology, could help identify patients who could benefit
from neoadjuvant therapy. Of note, LVI is not available on
conventional fine needle aspiration biopsy specimens but
may be evaluated in endoscopic mucosal resection (EMR)
or endoscopic submucosal dissection (ESD) specimens.
The authors also noted that neoadjuvant therapy could be
considered for patients with dysphagia despite T2N0
disease on EUS; retrospective data indicate that the greater
the extent of dysphagia, the higher the likelihood of T3
disease, with very high (>90%) specificity but low sensitivity.61 None of the studies within the meta-analyses
included a QoL component, and as noted by Kidane et al,
QoL assessments need to be a focus of future investigations
in this population to help guide shared-decision making.18
In the phase 3 ChemoRadiotherapy for Oesophageal
cancer followed by Surgery Study (CROSS), locoregionally
advanced patients (81% T3, 64% Nþ) were randomized to
surgery alone versus nCRT with carboplatin/paclitaxel
concurrent with RT to 41.4 Gy/23 fractions.14 OS was
significantly improved with nCRT for adenocarcinoma
(median OS: 43.2 vs 27.1 months, P Z .038) and SCC
patients (81.6 vs 21.1 months, P Z .008), and no differences in postoperative mortality or complications were
noted. In a subsequent secondary analysis of the patients on
the CROSS trial, although health-related QoL declined
during nCRT, no persistent degradation of health-related
QoL due to nCRT was identified compared with surgery
alone on further follow-up.15 Contemporary meta-analyses
of RCTs have found that nCRT provides significant improvements compared with surgery alone in OS, R0
resection rate, and locoregional control, with similar postoperative mortality.13,16 On subset analysis by histology,
Feng et al performed a meta-analysis including the initial
report of the CROSS study and found that OS was significantly improved for adenocarcinoma, whereas in the
analysis by Liu et al that included fewer adenocarcinoma
studies, the benefit only trended toward significance.
It should also be noted that each of these meta-analyses
included FFCD 9901, and the early stage patients in that
series may have dampened the magnitude of the overall OS
benefit from nCRT. Therefore, nCRT followed by surgery
appears to provide an OS benefit compared with surgery
alone for locoregionally advanced (ie, T3 and/or Nþ) patients. Neoadjuvant chemoradiation has the potential to
benefit T2N0 adenocarcinoma patients with high-risk features (length >3 cm, high grade, LVI on EMR/ESD) and/or
symptoms of dysphagia, as these factors are associated with
clinical understaging (Table 2, Variant 1).
nCRT with or without induction chemotherapy
In a randomized phase 2 trial, Ajani et al reported no significant increase in the primary endpoint of pathologic
complete response (pCR) rate when using treatment with or
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without induction chemotherapy involving 5-FU/oxaliplatin followed by nCRT to 50.4 Gy with concurrent 5-FU/
oxaliplatin compared with standard nCRT. Secondary
endpoints including OS and complications were similar.21
In a secondary subset analysis, induction chemotherapy
led to significantly improved OS for those with well- to
moderately differentiated adenocarcinoma but had no effect
on those with poor differentiation, leading to the hypothesis
that certain patients might still benefit from an induction
approach.22 In addition, in the phase 2R NEO-adjuvant
Study of Chemoradiotherapy in OesoPhagEal cancer
(NEOSCOPE) study, with a primary endpoint of pCR, patients were randomized to either carboplatin/paclitaxel or
capecitabine/oxaliplatin with RT to 45 Gy in 25 fractions
after 6 weeks of induction capecitabine/oxaliplatin; only
the carboplatin/paclitaxel arm achieved a pCR rate worthy
of further investigation (29.3% vs 11.1%, respectively).23
Induction chemotherapy is a promising approach for
esophageal cancer patients.
nCT versus nCRT
Although results are mixed regarding differences in outcomes between nCT and nCRT, RT appears beneficial
overall when added to chemotherapy in the neoadjuvant
setting for esophageal/GEJ adenocarcinoma patients. While
contemporary meta-analyses addressing adenocarcinoma
have shown that adding RT significantly increases the pCR
and R0 resection rates for esophageal/GEJ patients
compared with nCT alone, this addition has not translated
to an improvement in OS.24-26
As might be expected, RT decreased the risk of
locoregional relapse, but distant metastases-free survival
(DMFS) was not improved. Although a network metaanalysis of RCTs found perioperative 5-FU, leucovorin,
oxaliplatin, and docetaxel (FLOT) to be superior to all other
neoadjuvant regimens, it included all patients from the
FLOT4-AIO study in the analysis even though most patients had either gastric or Siewert III disease, limiting the
generalizability to esophageal or Siewert I-II GEJ adenocarcinoma.27,28 Long-term results of the initial report of the
phase 2R NeoRes I (NEOadjuvant chemotherapy versus
Radiochemotherapy for cancer of the ESophagus or cardia)
contained within these meta-analyses also noted that the
higher pCR found with nCRT versus nCT was not associated with an improvement in progression-free survival
(PFS) or OS.29 Patients on the nCRT arm received cisplatin/
5-FU concurrent with 40 Gy/20 fractions. Overall
treatment-related complications were similar, but fatal
postoperative complications were more common after
nCRT (9%) compared with nCT (1%) (P Z .02).29,30 A
secondary QoL analysis of the NeoRes I trial found a
significantly greater improvement in the dysphagia score
after nCT compared with nCRT, with the authors hypothesizing that RT-induced esophagitis led to worse
dysphagia.31 Also driving the results of these meta-analyses
were the phase 2R and 3 trials by Burmeister et al and Stahl
et al, respectively. Burmeister et al found an improvement
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in their primary endpoints of increased R0 resections and
pCR with nCRT (involving 35 Gy in 15 fractions) versus
nCT, making the addition of RT reasonable for locoregionally advanced disease.32 In the phase 3 PreOperative
therapy in Esophagogastric adenocarcinoma Trial (POET),
although the primary endpoint of OS was not met, value
was noted in the improved PFS with nCRT (both overall
and within the RT field involving 30 Gy in 15 fractions)
compared with nCT.33
Other authors have tried to increase the power of their
comparisons by performing network meta-analyses. Using
this technique, Chan et al found a significant OS and
locoregional control benefit with nCRT versus surgery
alone or with any of the other neoadjuvant therapies,
including nCT.34 There was a 97.5% probability on
Bayesian analysis that nCRT was the best regimen to
maximize OS; however, this came at a marginally significant risk for increased risk of postoperative mortality.
Although the OS benefit with nCRT only remained significant for SCC, the adenocarcinoma analysis was limited by
small patient numbers. Of note, compared with surgery
alone, none of the neoadjuvant therapies led to a significant
increase in postoperative mortality in direct pairwise
comparisons. Neoadjuvant chemoradiation was also found
to provide the optimal OS relative to other treatments in the
network meta-analysis performed by Cheng et al.35
Although they specifically excluded the FLOT4-AIO
study because of a lack of subgroup OS data on GEJ
cases, they did hypothesize that it might be worthwhile to
assess FLOT further in the treatment of esophageal cancer.
In sum, nCRT provides a benefit in local control, PFS, and
pCR, at the risk of a slight increase in postoperative complications compared with nCT for esophageal adenocarcinoma (Tables 3-5, Variants 2-4).

Adjuvant therapy
CROSS and associated meta-analyses demonstrate the superiority of nCRT for locoregionally advanced esophageal
cancer (T3/Nþ).5 Consideration of adjuvant therapy may
occur when patients are upstaged after esophagectomy for
what is thought to be early stage disease. Although prospective data are sparse to guide adjuvant therapy when no
neoadjuvant therapy was already given, a growing body of
literature including meta-analyses helps guide practice.
Adjuvant chemoradiation versus surgery alone
Adjuvant CRT (aCRT) has been inconsistently described in
prospective and retrospective literature. Contemporary metaanalyses included RCTs as well as prospective and retrospective studies.36,37 The meta-analysis by Luo et al
compared aCRT with surgery alone and demonstrated an OS
benefit on subset analysis for Nþ patients. Local control was
improved with aCRT, but not DMFS. Toxicity was noted to
be similar with no increase in pneumonitis, anastomotic
stenosis, or hematologic toxicities, and the esophagitis
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experienced was mild and easily managed. In the metaanalysis by Kang et al, aCRT was compared with a group
that consisted of surgery alone, adjuvant chemotherapy
(aCT), or adjuvant RT. Treatment within the aCRT group was
associated with a significant OS and locoregional control
benefit without increased severe complications. About 5%
had adenocarcinoma (n Z 117), bringing into question the
applicability of the overall results to this histology.
Pasquali et al performed a network meta-analysis of 33
RCTs comparing surgery alone to surgery plus nCT, neoadjuvant RT (nRT), nCRT, aCT, adjuvant RT, or aCRT.38 The
aggregate of neoadjuvant regimens was associated with
increased OS versus surgery alone, with nCRT being the only
regimen also independently associated with improved OS,
but the adjuvant regimens were not associated with improved
OS. The potential benefit to adjuvant therapy was likely
minimized by the suboptimal treatment completion rates,
noted to be only 48% to 64% in the following combined
gastric and GEJ trials. Results from a small phase 2R study
involving Siewert II/III patients suggest nCRT followed by
surgery may be a better tolerated treatment sequence than
surgery followed by aCRT.39 For INT-0116 (approximately
20% GEJ), aCRT compared with surgery alone provided a
benefit to OS, relapse-free survival, and locoregional control,
but not DMFS.40 The ChemoRadiotherapy after Induction
chemoTherapy In Cancer of the Stomach (CRITICS) trial
(17% GEJ) did not show a benefit to aCRT compared with
aCT for patients receiving nCT before surgery.41 After
upfront surgery, Cancer And Leukemia Group B (CALGB)
80801 (22% GEJ) found no benefit to adjuvant epirubicin,
cisplatin, and 5-fluorouracil (ECF) as opposed to 5-FU and
leucovorin given before and after aCRT.42 None of these
studies differentiated Siewert III versus I/II locations. No
studies meeting our selection criteria evaluated aCT after
nCRT and surgery, and therefore no high-level evidence exists to support this approach. Based on the limited data,
however, aCRT has been used with apparent success in the
general GEJ setting.

Definitive chemoradiation
Definitive chemoradiation versus surgery alone or nCRT
In a meta-analysis by Ma et al comparing definitive chemoradiation (dCRT) to surgery alone for potentially
resectable patients, 2 of the 13 included studies included an
appreciable number (56% on average) of adenocarcinoma
patients, thus lowering the confidence of conclusions from
this analysis.43 For these Western studies that included
adenocarcinoma, the odds ratio favored surgery alone. In a
meta-analysis of 32 RCTs and observational studies
comparing dCRT vs nCRT followed by surgery, 2-, 3-, and
5-year OS were significantly lower for dCRT.44 When
analyzing studies with similar baseline patient prognostic
characteristics, no statistically significant differences at any
time point were found, but numerically the 5-year OS was
almost twice as high in the nCRT group. No OS subgroup
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analysis was possible for adenocarcinoma owing to the lack
of studies involving this histology. The authors noted that
many studies were published before the establishment of
the effective regimen used in CROSS, and they proposed
that contemporary nCRT patients might have better outcomes when treated according to the CROSS protocol.
Radiation Therapy Oncology Group (RTOG) 8501 and
later the Intergroup 0123 trial established chemotherapy
concurrent with 50 to 50.4 Gy in 25 to 28 fractions as a
potentially curative RT dose in the definitive treatment of
esophageal
cancer,
with
long-term
OS
(ie,
10-year) at approximately 20% for the predominately squamous cell (82%-86%) populations of patients.45-47 However,
for adenocarcinoma, OS decreased to less than 20% by 3
years, with 5-year OS at 13% and only 1 of 23 patients alive at
long-term follow-up. Higher RT doses did not result in
improved QoL or oncologic outcomes. Although with shorter
follow-up, the predominantly adenocarcinoma RTOG 0436
trial involving dCRT showed essentially equivalent 2-year
OS regardless of histology.48 None of these 3 trials
required patients to be unresectable for enrollment, and the
number of medically and technically operable patients was
not defined. Given these data, both dCRT and nCRT remain
options, although for optimal outcomes, surgery should be
strongly considered.

Chemotherapy
Chemotherapy regimens (nCT/nCRT/poCT)
Regarding nCT alone, in the phase 3 United Kingdom Medical
Research Council Oesophageal 05 (MRC OE05) trial for
adenocarcinoma patients, randomization to the more intensive
4 cycles of neoadjuvant epirubicin, cisplatin, and capecitabine
(ECX) versus 2 cycles of cisplatin and 5-FU did not improve
the primary endpoint of OS, and ECX is therefore not recommended.49 In the phase 2R Eastern Cooperative Oncology
Group (ECOG) 1201 trial for adenocarcinoma patients
assessing 2 novel concurrent chemotherapy regimens with RT
to 45 Gy, neither the paclitaxel/cisplatin nor irinotecan/
cisplatin arm was found to be superior to historic controls
involving 5-FU/platinum.50 In a network meta-analysis of 10
RCTs involving nCRT versus surgery alone, the authors
compared 2 common concurrent chemotherapy regimens and
found paclitaxel/platinum to be significantly better than 5-FU/
platinum, but only for SCC and not adenocarcinoma.51 In a
meta-analysis of 31 RCTs and observational studies, Wang et al
found that taxane-based regimens resulted in better OS than 5FU/platinum in the settings of nCT, nCRT, and dCRT, and they
provided improved response, disease control, and pathologic
response rates.52 However, taxane-based regimens were
significantly associated with toxicities including grade 3 to 4
leukopenia, neutropenia, and diarrhea, and there was no
breakdown in benefit by histology.
For chemotherapy-alone regimens, the FLOT4-AIO trial
demonstrated significantly improved OS with FLOT versus
ECF/ECX, making perioperative FLOT the regimen of
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choice in gastric cancer, a location that comprised 45% of
the patients in this trial. Although 23% were Siewert I, the
applicability of the trial results to the GEJ is in question
owing to the combined grouping of Siewert II and III patients and lack of subset analyses for the GEJ vs gastric
locations.28 Therefore, there is no clear optimal chemotherapy regimen, and regimens involving paclitaxel/platinum and 5-FU/platinum are reasonable when combined
with RT. Perioperative chemotherapy including FLOT may
carry promise in the setting of esophageal or Siewert
I/II GEJ cancers, but studies have not isolated outcomes for
these tumor locations in the setting of RT.
Targeted therapy
Several studies have investigated the addition of targeted
therapy in the treatment of esophageal/GEJ cancer including
bevacizumab, panitumumab, and cetuximab.53-55 In the United
Kingdom MRC ST03 trial, patients with adenocarcinoma
anywhere from the distal esophagus to stomach (44% lower
esophageal or Siewert I-II) were randomized to 3 cycles of
perioperative ECX with or without bevacizumab.53 There was
no difference in the primary endpoint of OS, and there were
significantly more wound healing complications with bevacizumab. In the phase 2R German Cancer Society study
involving 43% GEJ patients (Siewert undefined), the addition
of panitumumab to poCT did not improve the primary endpoint
involving downstaging, but the authors noted that plasma levels
of pathway-associated proteins might identify a group of patients who could benefit from epidermal growth factor
receptoredirected therapy.54 In the SAKK 75/08 trial, locoregionally advanced patients (63% adenocarcinoma) received
induction cisplatin/docetaxel, which was then also given
concurrently with nRT to 45 Gy in 25 fractions.55 Although the
experimental arm involving cetuximab given during induction
and concurrent chemotherapy as well as adjuvantly did not
improve the primary endpoint of DFS, the secondary endpoint
of locoregional failure for R0 patients was significantly
improved. On subset analysis, the OS for adenocarcinoma was
improved, albeit nonsignificantly, from 3.2 to 5.1 years. The
authors of the SAKK 75/08 trial recognized that the RTOG
0436 and SCOPE-1 studies did not find a benefit to cetuximab
in the definitive setting, so they hypothesized that a benefit
might be limited to those receiving surgery.48,56 As of now,
there is no clear indication for targeted therapy in esophageal
adenocarcinoma.

Radiation therapy
Simulation, treatment technique, and radiation dose
In modern RT practice, treatment volumes are defined
based on the International Commission on Radiation Units
definitions of clinical target volume (CTV) and planning
target volume (PTV), using 3D conformal or intensity
modulated RT (IMRT) techniques.14,23,33 Highly conformal
radiation techniques integrating computed tomography
(CT)ederived images and PET imaging allow for greater
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sparing of normal tissues, particularly the lungs and heart,
while defining target volumes with greater specificity.23,60
Simulation
As a first step in radiation treatment planning, CT simulation is done using appropriate immobilization (eg, VacLok), supine with arms raised.23 Primary tumor localization
may be assisted by small-volume oral contrast showing
esophageal lumen narrowing with dilation superiorly. A 4dimensional CT simulation should be obtained if available
to assess excursion of the target areas over time, especially
for more distal tumors that might extend to the more mobile
GEJ and stomach.23,60
Radiation volumes
For neoadjuvant RT, the gross tumor volume (GTV) is based
on the extent of disease (prechemotherapy if induction
chemotherapy was given) using the initial PET/CT scan,
endoscopy report, and CT scan.2,14,23,33 The entire circumference of the esophageal wall, including any disease that
extended through the wall, should be contoured as GTV,
including any PET-avid or enlarged lymph nodes. Regarding
CTV creation, trials included in this review have delineated the
margin between 2 and 4 cm beyond the proximal and distal
edges of the esophageal GTV, or 0.5 to 1 cm beyond any
grossly involved paraesophageal nodes, whichever expansion
is larger. The panel favors a 3- to 4-cm longitudinal expansion
from the esophageal GTV, except for distal esophageal or GEJ
tumors, where a 2- to 3-cm margin caudally along clinically
uninvolved gastric mucosa is recommended.14,23,33 The CTV
should include the esophageal GTV with a 1-cm margin
radially to cover the paraesophageal nodal region, including a
0.5- to 1-cm expansion past any grossly involved node,
respecting anatomic boundaries.14,23,33 The CTV expansion
should be 0.5 cm into uninvolved organs (eg, heart, lungs,
liver), given the low likelihood of microscopic extension in the
absence of gross invasion.23 For distal tumors involving or
approaching the GEJ, the CTV should include the celiac and
subdiaphragmatic/paracardial nodes. For distal tumors in
which the CTV but not the GTV extends superiorly to the
mediastinum, it is not necessary to deliberately include the
anteriorly located superior mediastinal nodal stations electively other than would be encompassed by a 1-cm radial
expansion of the esophagus.23,60 However, for primary tumors
extending proximally to the carina, in addition to supraclavicular nodes, upper mediastinal (prevascular/paraortic/
aortopulmonary window/paratracheal/subcarinal) nodes may
be considered for inclusion.60 Splenic nodes are not typically
included for esophageal or GEJ Siewert I-II tumors. In a single
trial that involved radiating splenic nodes, the target was
defined as the region adjacent to the proximal 2 cm of the
splenic artery; this area might be incidentally included for
tumors with a large amount of gastric involvement.33
In the CROSS trial, most patients had either distant
failure or combined distant and locoregional recurrence.57
Elective nodal coverage was not required, and the exact
details of coverage were not described. Less than 5% of
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patients recurred in the supraclavicular fossa in both the
surgery alone and nCRT groups despite infrequent
coverage, but only 2% of the patients had proximal thoracic
esophagus tumors, with the overall location breakdown also
including 13% middle thoracic and 82% distal thoracic/
GEJ. This finding suggests that inclusion of the supraclavicular area appears unnecessary for most middle and
distal tumors, and the panel thus recommends limiting
elective radiation of the supraclavicular regions to tumors
extending superiorly to the carina. Only 7% (n Z 11) of the
surgery-alone arm versus 4% (n Z 8) of the nCRT group
experienced a celiac axis failure (P Z nonsignificant), of
which 90% involved distal tumors, and most patients had
experienced concurrent systemic metastases. A total of
38% (n Z 3) of the celiac failures in the nCRT group were
at the edge of the RT field. Mediastinal recurrences
occurred in 21% versus 7% of the surgery-alone versus
nCRT patients, although it is not clear whether the term
mediastinum refers to anterior nonparaesophageal nodal
stations. Also, in the CROSS trial, compared with SCC in
the surgery-alone arm, adenocarcinomas were less likely to
experience a locoregional relapse (30% vs 47%, respectively), but this difference between histologies did not exist
in the setting of nCRT (13% vs 14%). For patients undergoing nCRT, 91% of the recurrences involved a distant
component.
For PTV delineation, an expansion of the CTV by 0.5 to
1 cm in all directions is typical.23,33 For tumors involving
the distal esophagus and GEJ, it is important that respiratory motion be considered, especially when using highly
conformal techniques (eg, IMRT). This should include, at a
minimum, fluoroscopic or 4-dimensional CT imaging to
evaluate the degree of superior-inferior motion due to
respiration, which can then be incorporated into the PTV
margin.23 Daily image guided RT should be strongly
considered, especially for PTV expansions <0.7 cm, and
because GEJ tumors can vary in location owing to diaphragmatic motion.
Dose
For preoperative RT doses of 41.4 to 50.4 Gy (1.8-2 Gy/
fraction) are recommended, delivered to 95% of the PTV,
with the planning objectives placing the highest priority on
achieving PTV coverage and minimizing the doses to the
heart and lungs.14,17,23,29 The well-tolerated neoadjuvant
dose of 41.4 Gy used in the CROSS protocol allowed a 94%
resection rate, with 1% of patients having grade 3 esophagitis. Only 5% of patients experienced an in-field failure,
indicating that this dose is effective, with no improved outcomes noted with higher doses. However, significant caution
must be exercised to ensure patients receiving <50 Gy proceed to surgery as planned, so consider devising a radiation
plan for 50 to 50.4 Gy at the start of nCRT, with the goal of
stopping at 41.4 Gy if surgery is assured. Although long-term
QoL in the CROSS study was similar with and without nCRT,
this reassuring finding has not yet been reported with higher
RT doses. In the definitive setting, RT doses higher than 50.4
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Gy have not been shown to increase OS, locoregional control,
or QoL; thus, 50 to 50.4 Gy in 25 to 28 fractions is typically
preferred.45-47 Although the literature involves doses ranging
from 45 to 60 Gy in the postoperative setting, typically
adjuvant radiation is given 3 to 4 weeks after the operation,
with a dose in the range of 45 to 50.4 Gy because of inconclusive evidence of a benefit with higher doses.37,40,41 Given
the potential for increased toxicity with no benefit to higher
doses in the definitive setting, there also does not appear to be
any indication for escalating the dose beyond 54 Gy to the
anastomosis when given adjuvantly. An initial dose of 41.4 to
45 Gy to a target including elective regions followed by a
boost to a reduced volume focused on gross disease to 50.4
Gy can be considered to reduce doses to adjacent organs at
risk. If organ at risk dose limits cannot be respected with 3D
conformal therapy, IMRT should be considered and may
carry benefit particularly for cardiac sparing.60

Limitations
Although the literature search limited its results to papers
published between 2009 and 2019, 20 meta-analyses were
included, many of which included papers published before
this period. This increased the heterogeneity in staging
practices and tumor location categorization, and stage
migration occurred over time with PET/CT becoming part
of the standard workup. Although a strength of this
manuscript is the inclusion of only phase 3 or randomized
phase 2 experimental trials, many meta-analyses also
included observational studies, thereby decreasing the
overall study quality of those manuscripts. The majority of
patients in many series, especially those with predominately Eastern populations, had SCC histology. Despite
enforcing a minimum number of adenocarcinoma patients
required for inclusion (n Z 20), often the number of
adenocarcinoma patients was too small for subset analyses,
thus potentially limiting the generalizability of the results.

Future Directions
Outcomes for esophageal adenocarcinoma remain suboptimal, and ongoing clinical trials are exploring different
fields of research such as (1) the early assessment of tumor
responsiveness by PET imaging to direct subsequent therapies; (2) the comparison of more intensive neoadjuvant/
perioperative systemic therapy with nCRT; (3) novel radiation techniques including proton beam therapy; and (4)
integration of immunotherapy/targeted agents/radiosensitizers into classical nCRT platforms of preoperative
trials. Although pCR has been found to be prognostic, a
meta-analysis found that both DFS and pCR do not reliably
correlate with OS for GEJ cancers undergoing neoadjuvant
therapy.62 Therefore, OS remains the gold standard primary
endpoint, and it should be evaluated when feasible.
With the goal of learning the optimal radiosensitizing
chemotherapy regimen to use during nCRT, CALGB 80803
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was a phase 2R study that randomized patients to 6 weeks of
either induction folinic acid, 5-FU, and oxaliplatin (FOLFOX) or carboplatin/paclitaxel (NCT01333033).63 Responders based on PET scan reassessment continued the
same regimen, whereas nonresponders changed to the other
regimen during concurrent RT to 50.4 Gy/28 fractions. Initial
results showed that the pCR rate for nonresponders was high
enough to be considered a positive trial, but there was no
head-to-head comparison with nonresponders who
continued the same regimen. Research efforts to help avoid
the morbidity of surgery include the Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in
Operable Oesophageal Cancer With a Complete Clinical
Response to Radiochemotherapy study (NCT02551458).
With perioperative FLOT now established as a standard of
care option for gastric cancer, the Preoperative Chemotherapy vs. Chemoradiation in Esophageal/GEJ Adenocarcinoma (POWERRANGER) trial seeks to investigate
whether this regimen or perioperative ECF/ECX offers any
advantages versus nCRT with concurrent carboplatin/paclitaxel for esophageal or Siewert I-II GEJ adenocarcinomas
(NCT01404156).28 A randomized phase 2B trial identified
decreased side effects with proton beam therapy versus
IMRT as measured by the metric “total toxicity burden,”64
leading to the phase 3 NRG GI-006 trial comparing these
modalities (NCT03801876). Preliminary results from phase
3 RTOG 1010 (NCT01196390) did not find any benefit to
DFS when trastuzumab was added both concurrently with
nCRT and adjuvantly for operable HER2-overexpressing
esopahgeal adenocarcinoma.65 More encouraging are initial
results of the Phase 3 CheckMate 577 study (NCT02743494),
which showed that PD-1 inhibitor nivolumab given adjuvantly for esophageal/GEJ patients who had residual disease
following nCRT and surgery improved the primary endpoint
of DFS.66 These various investigations provide hope toward
further improving clinical outcomes.

Conclusions: Summary of Panel
Recommendations
 For a medically operable nonmetastatic patient with a cT3
and/or cNþ adenocarcinoma of the esophagus or GEJ
(Siewert I-II) the panel:
1. Recommends strongly that nCRT is usually appropriate.
2. Recommends that induction chemotherapy followed by
nCRT may be appropriate.
3. Recommends with reservations nCT alone or poCT may
be appropriate.
4. Does not recommend definitive chemoradiation without
surgery unless surgery is declined.
 For a medically operable patient with cT2N0M0 adenocarcinoma of the esophagus or GEJ (Siewert I-II) with
high-risk features including length >3 cm, high-grade
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pathology, symptoms of dysphagia, and/or if pathology
from EMR/ESD shows lymphovascular invasion, the
panel recommends that nCRT is usually appropriate.
 For a patient with adenocarcinoma of the esophagus or
GEJ (Siewert I-II) found to have pathologically involved
nodes (pNþ) who did not receive neoadjuvant therapy,
the panel recommends that adjuvant chemoradiation is
usually appropriate.
 In the setting of nCRT for adenocarcinoma of the
esophagus or GEJ (Siewert I-II), the panel strongly recommends that a radiation dose between 40 and 50.4 Gy
in daily fractions sizes between 1.8 and 2.0 Gy to
involved disease and elective nodal areas is usually
appropriate.
 In the setting of adjuvant chemoradiation for adenocarcinoma of the esophagus or GEJ (Siewert I-II), the panel
strongly recommends that a radiation dose between 45
and 50.4 Gy in daily fraction sizes between 1.8 and 2.0
Gy to involved disease, the anastomosis, and elective
nodal areas is usually appropriate.
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